Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

29,909 total articles

U.S. Drives a Third of 2025 Global CO2 Uptick as Coal Use Rebounds

U.S. Drives a Third of 2025 Global CO2 Uptick as Coal Use Rebounds

A report from the Energy Institute, produced with Ember, Kearney Institute and KPMG, attributes roughly one-third of the 2025 increase in global energy-sector CO2 emissions to the United States. The rise was linked to a 10% jump in U.S. coal consumption and broader trends including faster growth in electricity demand than supply, stronger renewable…

European banks urge regulators to avoid curbing off-exchange equity trading

European banks urge regulators to avoid curbing off-exchange equity trading

A coalition of Europe’s biggest banks and trading firms has called on regulators to refrain from imposing new restrictions on off-exchange equity trading. The Association for Financial Markets in Europe (AFME) argues that the decline in trading on traditional exchanges has not demonstrably undermined price-setting and that stricter rules could degr…

TD Cowen Picks Immatics as Its Leading SMIDCAP Pharma Choice for 2026

TD Cowen Picks Immatics as Its Leading SMIDCAP Pharma Choice for 2026

TD Cowen has named Immatics N.V. as its top small and mid-cap pharmaceutical selection for 2026, citing an underappreciated commercial opportunity for the company's PRAME-directed cell therapy program. The firm keeps a Buy rating on Immatics and points to a de-risked Phase III candidate, potential differentiation versus a competitor, and a sizable …

SeeQC Files for Nasdaq IPO, Pursues Capital and Concurrent Merger

SeeQC Files for Nasdaq IPO, Pursues Capital and Concurrent Merger

SeeQC, a quantum computing hardware company focused on superconducting digital control and quantum-classical integration, has filed for an initial public offering to list on the Nasdaq Global Market under the ticker SEQC. The registration does not yet specify the number of shares or price range. The offering is being coordinated with a merger invol…

Moscow stocks close higher as oil, power and mining boost MOEX

Moscow stocks close higher as oil, power and mining boost MOEX

Russian equities closed higher on Monday with the MOEX Russia Index rising 2.90% as advances in Oil & Gas, Power and Mining stocks propelled the market. Magnitogorskiy Metallurgicheskiy Kombinat, Aeroflot and PIK Group were among the session's strongest performers. Market breadth was strongly positive while the Russian Volatility Index (RVI) moved …

PACS Group to Add 34 Skilled Nursing Facilities in Multi-State Deal

PACS Group to Add 34 Skilled Nursing Facilities in Multi-State Deal

PACS Group Inc. announced it will acquire 34 skilled nursing facilities from Eduro Healthcare, adding 3,633 beds across six western states and expanding the company’s operational footprint into four new states. Shares of PACS rose in after-hours trading following the disclosure. The transaction is structured to close in multiple tranches, with most…

After-Hours Movers: Big Gains for AeroVironment and SharonAI, Sharp Pullbacks at Concentrix, Vishay, Praxis Update

After-Hours Movers: Big Gains for AeroVironment and SharonAI, Sharp Pullbacks at Concentrix, Vishay, Praxis Update

Stocks moved sharply in after-hours trading as a handful of companies reported results, filings or regulatory actions that altered near-term investor calculus. AeroVironment jumped after a notable quarterly beat and raised revenue outlook; Praxis Precision Medicines saw its FDA review extended; Vishay announced a large equity offering; Concentrix c…

Genmab Shares Climb After EPCORE DLBCL-4 Trial Meets Primary Endpoint

Genmab Shares Climb After EPCORE DLBCL-4 Trial Meets Primary Endpoint

Genmab A/S stock jumped in after-hours trading after the company reported positive topline results from the Phase 3 EPCORE DLBCL-4 trial. The study, evaluating subcutaneous epcoritamab in combination with lenalidomide against standard-of-care therapy in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), met its primary endpoi…